Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b-meningococcal group C conjugate vaccine + Infanrix Penta
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
This is a **combination vaccine** that includes two components: - **Haemophilus influenzae type b-meningococcal group C conjugate vaccine**: A vaccine designed to induce immunity against invasive disease caused by _Haemophilus influenzae_ type b (Hib) and _Neisseria meningitidis_ group C. This component works by presenting polysaccharide antigens from the bacterial capsules that are conjugated to a carrier protein (often tetanus toxoid), thereby stimulating a robust T-cell dependent immune response, especially in infants and young children[2][3][7]. - **Infanrix Penta**: A pentavalent combination vaccine containing inactivated diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (PT, FHA, PRN), inactivated poliovirus types 1, 2, 3, and hepatitis B surface antigen. It is designed to protect against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and hepatitis B. All components are inactivated/toxoid or recombinant and function by stimulating antibody and cellular immune responses targeting the respective pathogens[3]. This combination vaccine is intended for pediatric use to streamline immunization schedules, improve coverage, and reduce the number of injections needed[3][7].
- Brand names
- Hib-MenC conjugate vaccine + Infanrix Penta
- Other names
- Hib-MenC conjugate vaccine + Infanrix Penta
02
Targets
Neisseria meningitidis group C capsular polysaccharideHBsAg (Hepatitis B surface antigen)Diphtheria toxinFHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)PRN (Pertactin)
Beyond the preview
Go deeper on haemophilus influenzae type b-meningococcal group C conjugate vaccine + Infanrix Penta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b-meningococcal group C conjugate vaccine + Infanrix Penta.